COMPARISON OF SOLIFENACIN VERSUS COMBINATION OF SOLIFENACIN AND TAMSULOSIN IN IMPROVING UNILATERAL DOUBLE-J STENT RELATED LOWER URINARY TRACT SYMPTOMS - A PROSPECTIVE RANDOMIZED CONTROL TRIAL

Authors

  • Muhammad Tanveer Sajid Armed Forces Institute of Urology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Sami Ur Rehman Armed Forces Institute of Urology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Muhammad Akmal Armed Forces Institute of Urology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Hussain Ahmad Armed Forces Institute of Urology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Zahoor Iqbal Mirza Armed Forces Institute of Urology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Arshad Mahmood Armed Forces Institute of Urology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v71i1.2617

Keywords:

LUTS, solifenacin, Ureteric stent-related symptoms, tamsulosin, IPSS

Abstract

Objective: To compare Solifenacin versus solifenacin plus tamsulosin in terms of international prostate symptom score (IPSS) for lower urinary tract symptoms (LUTS) in patients with unilateral double-J (DJ) ureteric stents.

Study Design: Comparative cross sectional study.

Place and Duration of Study: Armed Forces Institute of Urology, Rawalpindi from Sep 2018 to Feb 2019.

Methodology: A total of two hundred (n=200) patients of either gender aged 20-50 years, who underwent
unilateral DJ stenting for different endourological procedures, were enrolled after satisfying inclusion/exclusion
criteria and then randomly allocated to group A (Solifenacin 5mg once daily (OD) ± placebo for 2 weeks) or group B (Solifenacin 5mg OD ± Tamsulosin 0.4 mg OD for 2 weeks) respectively. Baseline (1st post-operative day) and Post 02 weeks treatment IPSS was recorded and analyzed.

Results: Mean age of presentation in group A and group B was 41.11 ± 6.45 vs 39.86 ± 5.34 years with p-value 0.14. Majority of patients in both groups were male (34% female in group A while 31% in group B, difference being statistically insignificant p 0.65). Baseline IPSS in group A and group B was 10.33 ± 2.72 vs 10.46 ± 3.12 with pvalue 0.76 (statistically insignificant) while post 02 weeks treatment IPSS in group A and B was 9.20 ± 2.67 vs 7.88 ± 2.63 respectively with p-value <0.001, the difference being statistically significant.

Conclusions: Current study revealed significant advantage of combination therapy (solifenacin ± tamsulosin)
compared with solifenacin monotherapy in lowering LUTS based on IPSS in patients having unilateral......

Downloads

Download data is not yet available.

Downloads

Published

23-02-2021

Issue

Section

Original Articles

How to Cite

1.
Sajid MT, Rehman SU, Akmal M, Ahmad H, Mirza ZI, Mahmood A. COMPARISON OF SOLIFENACIN VERSUS COMBINATION OF SOLIFENACIN AND TAMSULOSIN IN IMPROVING UNILATERAL DOUBLE-J STENT RELATED LOWER URINARY TRACT SYMPTOMS - A PROSPECTIVE RANDOMIZED CONTROL TRIAL. Pak Armed Forces Med J [Internet]. 2021 Feb. 23 [cited 2024 Jun. 25];71(1):45-50. Available from: https://pafmj.org/PAFMJ/article/view/2617